Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro

OBJECTIVES: Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer that carries an extremely poor prognosis. Up to 35% of USC may overexpress the epidermal growth factor receptor-2 (HER2/Neu) at strong (i.e., 3 +) level by immunohistochemistry (IHC) or harbor HER2/Neu gene amp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Tumour Biol
Autores principales: Zhu, Liancheng, Lopez, Salvatore, Bellone, Stefania, Black, Jonathan, Cocco, Emiliano, Zigras, Tiffany, Predolini, Federica, Bonazzoli, Elena, Bussi, Beatrice, Stuhmer, Zachary, Schwab, Carlton L., English, Diana P., Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Rutherford, Thomas J., Santin, Alessandro D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573583/
https://ncbi.nlm.nih.gov/pubmed/25669172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13277-015-3218-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares